[{"NetIncomeLoss_1_Q3_USD":-10181000.0,"GeneralAndAdministrativeExpense_1_Q3_USD":4481000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3_Q3_shares":12052876.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q3_shares":29664122.0,"DueFromRelatedPartiesCurrent_0_Q3_USD":527000.0,"IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_3_Q3_USD":-2.67,"IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_1_Q3_USD":-0.36,"CommitmentsAndContingencies_0_Q3_USD":null,"ContractualObligationDueInSecondAndThirdYear_0_Q3_USD":8418000.0,"InterestPaidNet_3_Q3_USD":295000.0,"IncomeTaxesPaid_3_Q3_USD":47000.0,"FairValueLiabilitiesLevel2ToLevel1TransfersAmount_0_Q3_USD":0.0,"NetCashProvidedByUsedInInvestingActivities_3_Q3_USD":621000.0,"PurchaseObligation_0_Q3_USD":7622000.0,"StockIssuedDuringPeriodValueNewIssues_1_Q3_USD":169541000.0,"InterestIncomeExpenseNonoperatingNet_3_Q3_USD":-660000.0,"InterestIncomeExpenseNonoperatingNet_1_Q3_USD":-226000.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_3_Q3_USD":0.0,"AssetsCurrent_0_Q3_USD":262404000.0,"OperatingLeaseExpense_3_Q3_USD":500000.0,"OperatingLeaseExpense_1_Q3_USD":100000.0,"LongTermDebt_0_Q3_USD":6856000.0,"LongTermDebtCurrent_0_Q3_USD":2571000.0,"CostsAndExpensesRelatedParty_3_Q3_USD":1075000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3_Q3_shares":4751842.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q3_shares":4751842.0,"StockIssuedDuringPeriodValueShareBasedCompensation_1_Q3_USD":299000.0,"CommonStockSharesIssued_0_Q3_shares":37107522.0,"ContractualObligationDueInFourthAndFifthYear_0_Q3_USD":62000.0,"Assets_0_Q3_USD":262449000.0,"GeneralAndAdministrativeExpense_3_Q3_USD":9126000.0,"DepreciationAndAmortization_3_Q3_USD":200000.0,"PurchaseObligationDueInSecondAndThirdYear_0_Q3_USD":1384000.0,"PreferredStockSharesOutstanding_0_Q3_shares":0.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q3_USD":34000.0,"ResearchAndDevelopmentExpense_3_Q3_USD":16819000.0,"ResearchAndDevelopmentExpense_1_Q3_USD":5328000.0,"WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_1_Q3_USD":1019000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q3_USD":380000.0,"IncomeTaxExpenseBenefit_3_Q3_USD":59000.0,"IncomeTaxExpenseBenefit_1_Q3_USD":35000.0,"PreferredStockDividendsIncomeStatementImpact_3_Q3_USD":5202000.0,"PreferredStockDividendsIncomeStatementImpact_1_Q3_USD":578000.0,"CommonStockValue_0_Q3_USD":37000.0,"StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1_Q3_USD":175043000.0,"DepreciationDepletionAndAmortization_3_Q3_USD":197000.0,"NetCashProvidedByUsedInFinancingActivities_3_Q3_USD":274520000.0,"FairValueAssetsLevel2ToLevel1TransfersAmount_0_Q3_USD":0.0,"ShareBasedCompensation_3_Q3_USD":3693000.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_3_Q3_USD":0.0,"DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_0_Q3_USD":240000.0,"PaymentsOfStockIssuanceCosts_3_Q3_USD":3183000.0,"LongTermDebtMaturingInYearsTwoAndThree_0_Q3_USD":6750000.0,"ProceedsFromSaleOfPropertyHeldForSale_3_Q3_USD":641000.0,"FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_3_Q3_USD":0.0,"AccruedLiabilitiesAndOtherLiabilities_0_Q3_USD":3205000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_3_Q3_USD":-32168000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_1_Q3_USD":-10759000.0,"IncreaseDecreaseInAccountsPayable_3_Q3_USD":-2323000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q3_USD":259484000.0,"AdditionalPaidInCapitalCommonStock_0_Q3_USD":351727000.0,"Liabilities_0_Q3_USD":10433000.0,"IncreaseDecreaseInOtherAccruedLiabilities_3_Q3_USD":1995000.0,"IncreaseDecreaseInOtherNoncurrentLiabilities_3_Q3_USD":-5000.0,"IncreaseDecreaseInDueFromRelatedPartiesCurrent_3_Q3_USD":-9000.0,"ConversionOfStockAmountConverted1_3_Q3_USD":175043000.0,"CommonStockCapitalSharesReservedForFutureIssuance_0_Q3_shares":7692751.0,"ContractualObligation_0_Q3_USD":14858000.0,"FairValueLiabilitiesLevel1ToLevel2TransfersAmount_0_Q3_USD":0.0,"PreferredStockDividendsAndOtherAdjustments_3_Q3_USD":5202000.0,"PreferredStockDividendsAndOtherAdjustments_1_Q3_USD":578000.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q3_USD":97000.0,"LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_0_Q3_USD":106000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3_Q3_USD":-26907000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q3_USD":-10146000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q3_USD":689000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-24674000.0,"ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear_0_Q3_USD":6378000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":12052876.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":29664122.0,"LiabilitiesCurrent_0_Q3_USD":7197000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_3_Q3_USD":250467000.0,"AccountsPayableCurrent_0_Q3_USD":1421000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q3_USD":259484000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q3_USD":2393000.0,"ProceedsFromStockOptionsExercised_3_Q3_USD":299000.0,"LongTermDebtNoncurrent_0_Q3_USD":3189000.0,"OtherAccruedLiabilitiesCurrent_0_Q3_USD":240000.0,"InterestExpenseDebt_3_Q3_USD":700000.0,"InterestExpenseDebt_1_Q3_USD":300000.0,"NumberOfOperatingSegments_3_Q3_Segment":1.0,"FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_3_Q3_USD":0.0,"LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_0_Q3_USD":3007000.0,"PreferredStockSharesIssued_0_Q3_shares":0.0,"ProceedsFromIssuanceOfConvertiblePreferredStock_3_Q3_USD":36228000.0,"PropertyPlantAndEquipmentNet_0_Q3_USD":45000.0,"NetIncomeLoss_3_Q3_USD":-26966000.0,"NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_3_Q3_USD":3000.0,"CommonStockSharesOutstanding_0_Q3_shares":37107522.0,"AssetImpairmentCharges_1_Q3_USD":0.0,"AssetImpairmentCharges_3_Q3_USD":0.0,"PreferredStockParOrStatedValuePerShare_0_Q3_USD":0.001,"ProceedsFromIssuanceOfCommonStock_3_Q3_USD":172724000.0,"CommonStockParOrStatedValuePerShare_0_Q3_USD":0.001,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3_Q3_USD":2137000.0,"FairValueAssetsLevel1ToLevel2TransfersAmount_0_Q3_USD":0.0,"CommonStockSharesAuthorized_0_Q3_shares":1000000000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":1182000.0,"OperatingIncomeLoss_3_Q3_USD":-25838000.0,"OperatingIncomeLoss_1_Q3_USD":-9809000.0,"OtherNonoperatingExpense_3_Q3_USD":409000.0,"OtherNonoperatingExpense_1_Q3_USD":111000.0,"PreferredStockValue_0_Q3_USD":null,"LiabilitiesAndStockholdersEquity_0_Q3_USD":262449000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q3_USD":1124000.0,"LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_0_Q3_USD":3743000.0,"PreferredStockSharesAuthorized_0_Q3_shares":100000000.0,"AllocatedShareBasedCompensationExpense_1_Q3_USD":689000.0,"PropertyPlantAndEquipmentGross_0_Q3_USD":142000.0,"OperatingExpenses_3_Q3_USD":27020000.0,"OperatingExpenses_1_Q3_USD":9809000.0,"EarningsPerShareBasicAndDiluted_3_Q3_USD":-2.67,"EarningsPerShareBasicAndDiluted_1_Q3_USD":-0.36,"ProfitLoss_3_Q3_USD":-26966000.0,"OtherLiabilitiesNoncurrent_0_Q3_USD":47000.0,"StockholdersEquity_0_Q3_USD":252016000.0,"PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_0_Q3_USD":6238000.0,"PaymentsToAcquirePropertyPlantAndEquipment_3_Q3_USD":20000.0,"DebtInstrumentCarryingAmount_0_Q3_USD":6000000.0,"AmortizationOfFinancingCostsAndDiscounts_3_Q3_USD":339000.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-99748000.0,"AllocatedShareBasedCompensationExpense_3_Q3_USD":3693000.0,"AccruedProfessionalFeesCurrent_0_Q3_USD":345000.0,"Ticker":"ALXO","CIK":"1810182","name":"ALX ONCOLOGY HOLDINGS INC","OfficialName":"ALX Oncology Holdings Inc. Common Stock","form":"10-Q","period":"20200930","fy":"2020.0","fp":"Q3","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"632216571.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20201112"}]